CP
NVO

Canopy Partners’s Novo Nordisk NVO Stock Holding History

Canopy Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$288K Buy
6,010
+306
+5% +$13.1K 0.09% 187
2026
Q1 		$210K Sell
5,704
-554
-9% -$26.3K 0.07% 221
2025
Q4 		$318K Sell
6,258
-248
-4% -$12.7K 0.1% 159
2025
Q3 		$361K Buy
6,506
+2
+0% +$117 0.12% 142
2025
Q2 		$449K Buy
6,504
+71
+1% +$4.83K 0.16% 116
2025
Q1 		$447K Sell
6,433
-112
-2% -$9.25K 0.17% 108
2024
Q4 		$563K Sell
6,545
-88
-1% -$9.52K 0.21% 94
2024
Q3 		$790K Sell
6,633
-185
-3% -$24.7K 0.34% 69
2024
Q2 		$973K Hold
6,818
– – 0.45% 43
2024
Q1 		$875K Buy
6,818
+882
+15% +$105K 0.43% 50
2023
Q4 		$614K Buy
+5,936
New +$587K 0.37% 66

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Canopy Partners's NVO Position: Q2 2026 in Review

Canopy Partners increased its Novo Nordisk (NVO) stake by 5.4% in Q2 2026, buying an estimated $13.1K and bringing the position to 6,010 shares worth $288K. The position accounts for 0.09% of the portfolio, ranked #187.

Canopy Partners first reported a position in NVO in Q4 2023 and has held it in 11 quarters since. The position peaked at $973K in Q2 2024. 379 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Canopy Partners held 6,010 shares of Novo Nordisk worth $288K as of Q2 2026.
  • Canopy Partners bought 306 Novo Nordisk shares in Q2 2026, an estimated $13.1K.
  • Novo Nordisk made up 0.09% of Canopy Partners's portfolio in Q2 2026, its #187 holding.
  • Canopy Partners first reported a position in Novo Nordisk in Q4 2023 and has held it in 11 quarters since.
  • Canopy Partners's Novo Nordisk position peaked at $973K in Q2 2024.
  • 379 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Canopy Partners's 13F filing for Q2 2026, filed 22 Jul 2026.